Editas Medicine, Inc.
EDIT•NASDAQ•Healthcare•Biotechnology

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOGilmore O’Neill
Founded2013
IPO DateFebruary 3, 2016
Employees246
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.editasmedicine.com
Phone617 401 9000
Address
11 Hurley Street Cambridge, Massachusetts 02141 United States

Corporate Identifiers

CIK0001650664
CUSIP28106W103
ISINUS28106W1036
EIN46-4097528
SIC2836

Leadership Team & Key Executives

Dr. Gilmore O'Neill M.D.
President, Chief Executive Officer and Director
Dr. Feng Zhang Ph.D.
Co-Founder and Scientific Advisory Board Member
Dr. George McDonald Church Ph.D.
Co-Founder and Scientific Advisory Board Member
Amy Parison
Senior Vice President and Chief Financial Officer
Gregory Whitehead
Executive Vice President and Chief Technical and Quality Officer
Dr. Linda C. Burkly Ph.D.
Executive Vice President and Chief Scientific Officer
Cristi Barnett
Senior Vice President of Corporate Communications and Investor Relations
Damien Grierson J.D.
Senior Vice President, General Counsel and Corporate Secretary
Frank Panaccio
Senior Vice President and Chief Business Officer
Brieana Buckley
Senior Vice President of Development and Program Leadership